Analysis of the CD8+ T cell population revealed that EOMES lysine 641 was acetylated in 70% of CD8+ tumor-infiltrating lymphocytes in resistant patients vs. only 4.8% in responders, whereas the same motif was methylated in 54% of responders and 22.5% of resistant melanoma tissues (Figure 7G). The gene discussed is CD8A; the disease is neoplasm.